Implementing improved analytical methods to support vaccine quality - Part 2 (from Sep 16)

Implementing improved analytical methods to support vaccine quality - Part 2 (from Sep 16)

Thursday, September 24, 2020 7:40 PM to 9:50 PM · 2 hr. 10 min. (Africa/Abidjan)
Pre-congress workshops
Vaccine Showcases

Information

Watch on demand on Sep 24, or join LIVE on Sep 16 by registering here:

www.attendee.gotowebinar.com/register/2039692334803885581


Workshop opening remarks

Dr Maura C. Kibbey, Senior Scientific Fellow, Education & Training, Global Biologics, USP

Strategies for vaccine development and lifecycle management 

Sabrina Restrepo, Director, Global Vaccines Technical Operations, Merck

The overall control strategy as tool to develop and advance new vaccine platforms

Marta Isabel da Conceição Carreira Germano, Scientific Director Group Head of Product Characterization, Janssen 

Potency testing for vaccines- challenges and opportunities from development to commercial lifecycle

Dr Jean-Francois Dierick, Global Subject Matter Expert, Analytical Method Validation & Dr Xianzhi Zhou, Bioassay Manager, GSK Vaccines

Industry perspective on implementing novel analytical technologies for viral vector-based vaccines

Mark van Oojj, Scientific Director, PER.C6 technical lead/ Head of Platform innovation and implementation, Janssen

Panel with all speakers 

Moderated by Dr Dirk Redlich, VP, Head CMC Development and Clinical Trial Material Manufacturing, Janssen

Log in